US 12,285,482 B2
Therapeutic vaccine for Hepatitis B virus (HBV) using the HBV PreS1 and/or PreS2, and/or S-HBsAg regions of the HBV envelope protein
Edward A. Clark, Seattle, WA (US); Che-Leung Law, Seattle, WA (US); Deborah Fuller, Seattle, WA (US); and Michael Gale, Seattle, WA (US)
Assigned to UNIVERSITY OF WASHINGTON, Seattle, WA (US); and ABACUS BIOSCIENCE, INC., Sammamish, WA (US)
Filed by University of Washington, Seattle, WA (US); and ABACUS BIOSCIENCE, INC., Sammamish, WA (US)
Filed on Jul. 1, 2022, as Appl. No. 17/810,480.
Application 17/810,480 is a continuation of application No. 16/764,950, granted, now 11,389,532, previously published as PCT/US2018/061218, filed on Nov. 15, 2018.
Claims priority of provisional application 62/587,051, filed on Nov. 16, 2017.
Prior Publication US 2023/0053634 A1, Feb. 23, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/29 (2006.01); A61K 39/00 (2006.01); A61P 31/20 (2006.01); C07K 16/28 (2006.01)
CPC A61K 39/292 (2013.01) [A61P 31/20 (2018.01); C07K 16/2878 (2013.01); C07K 16/2896 (2013.01); A61K 2039/6056 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01)] 20 Claims
 
1. A nucleic acid encoding a polypeptide comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:67 residues 21-697.